{"transactions":[{"id":4637798,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-08T20:07:04.000Z","date":"2026-10-07","kind":"sale","planned":true,"acquired":false,"shares":1147,"price":30.66,"value":35167.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.33 to $30.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":452245,"source":{"system":"sec-edgar","filing":"0001193125-26-417919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526417919/ownership.xml","form_type":"4"}},{"id":4637797,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-08T20:07:04.000Z","date":"2026-10-06","kind":"sale","planned":true,"acquired":false,"shares":3375,"price":32.0314,"value":108105.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.65 to $32.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":453392,"source":{"system":"sec-edgar","filing":"0001193125-26-417919","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526417919/ownership.xml","form_type":"4"}},{"id":4634269,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-10-02T00:30:09.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":2075,"price":33.7556,"value":70042.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $33.64 to $34.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":139914,"source":{"system":"sec-edgar","filing":"0001193125-26-410734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526410734/ownership.xml","form_type":"4"}},{"id":4634268,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-10-02T00:30:09.000Z","date":"2026-09-30","kind":"sale","planned":true,"acquired":false,"shares":7925,"price":33.0364,"value":261813.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.64 to $33.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":141989,"source":{"system":"sec-edgar","filing":"0001193125-26-410734","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526410734/ownership.xml","form_type":"4"}},{"id":4626010,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":43,"price":41.05,"value":1765.15,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."}],"balance_after":456767,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4626009,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":215,"price":39.8602,"value":8569.943,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.57 to $40.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":456810,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4626008,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-24T20:05:09.000Z","date":"2026-09-23","kind":"sale","planned":true,"acquired":false,"shares":1952,"price":39.0523,"value":76230.0896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.54 to $39.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":457025,"source":{"system":"sec-edgar","filing":"0001193125-26-401017","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526401017/ownership.xml","form_type":"4"}},{"id":4613250,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:05:05.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":1069,"price":46.0147,"value":49189.7143,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.95 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":458977,"source":{"system":"sec-edgar","filing":"0001193125-26-386436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526386436/ownership.xml","form_type":"4"}},{"id":4613249,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-09-09T20:05:05.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":7141,"price":45.555,"value":325308.255,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $44.94 to $45.90, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":460046,"source":{"system":"sec-edgar","filing":"0001193125-26-386436","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526386436/ownership.xml","form_type":"4"}},{"id":675225,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:05:03.000Z","date":"2026-08-25","kind":"sale","planned":true,"acquired":false,"shares":18921,"price":49.5723,"value":937957.4883,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.03 to $50.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":467187,"source":{"system":"sec-edgar","filing":"0001193125-26-368285","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526368285/ownership.xml","form_type":"4"}},{"id":675235,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:00:03.000Z","date":"2026-08-25","kind":"sale","planned":true,"acquired":false,"shares":16201,"price":51.0576,"value":827184.1776,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.91 to $51.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":195862,"source":{"system":"sec-edgar","filing":"0001193125-26-368244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526368244/ownership.xml","form_type":"4"}},{"id":675234,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:00:03.000Z","date":"2026-08-25","kind":"sale","planned":true,"acquired":false,"shares":20799,"price":50.3111,"value":1046420.5689,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":212063,"source":{"system":"sec-edgar","filing":"0001193125-26-368244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526368244/ownership.xml","form_type":"4"}},{"id":675233,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-08-26T20:00:03.000Z","date":"2026-08-24","kind":"sale","planned":true,"acquired":false,"shares":13160,"price":49.9983,"value":657977.628,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.90 to $50.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":232862,"source":{"system":"sec-edgar","filing":"0001193125-26-368244","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526368244/ownership.xml","form_type":"4"}},{"id":680222,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-08-20T20:09:03.000Z","date":"2026-08-19","kind":"sale","planned":true,"acquired":false,"shares":404,"price":49.9,"value":20159.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."}],"balance_after":246022,"source":{"system":"sec-edgar","filing":"0001193125-26-359189","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526359189/ownership.xml","form_type":"4"}},{"id":689466,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":5794,"price":48.6229,"value":281721.0826,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.45 to $48.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":486108,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689465,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":19500,"price":48.0434,"value":936846.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $47.45 to $48.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":491902,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689464,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-11","kind":"sale","planned":true,"acquired":false,"shares":3664,"price":46.8988,"value":171837.2032,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.32 to $47.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":511402,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689463,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":8370,"price":46.7479,"value":391279.923,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.38 to $47.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":515066,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":689462,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-12T20:35:43.000Z","date":"2026-08-10","kind":"sale","planned":true,"acquired":false,"shares":14171,"price":45.9736,"value":651491.8856,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.37 to $46.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":523436,"source":{"system":"sec-edgar","filing":"0001193125-26-346995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526346995/ownership.xml","form_type":"4"}},{"id":701572,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:02.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":7,"price":42.735,"value":299.145,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."}],"balance_after":537607,"source":{"system":"sec-edgar","filing":"0001193125-26-323637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526323637/ownership.xml","form_type":"4"}},{"id":701571,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-29T20:05:02.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":2203,"price":42.107,"value":92761.721,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.66 to $42.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":537614,"source":{"system":"sec-edgar","filing":"0001193125-26-323637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526323637/ownership.xml","form_type":"4"}},{"id":709179,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-15T20:15:03.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":2729,"price":40.5724,"value":110722.0796,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.37 to $40.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":539817,"source":{"system":"sec-edgar","filing":"0001193125-26-304786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526304786/ownership.xml","form_type":"4"}},{"id":709178,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-15T20:15:03.000Z","date":"2026-07-14","kind":"sale","planned":true,"acquired":false,"shares":5481,"price":39.7217,"value":217714.6377,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.36 to $40.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":542546,"source":{"system":"sec-edgar","filing":"0001193125-26-304786","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526304786/ownership.xml","form_type":"4"}},{"id":721546,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:10:03.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":43.1547,"value":43154.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.81 to $43.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":149914,"source":{"system":"sec-edgar","filing":"0001193125-26-292546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292546/ownership.xml","form_type":"4"}},{"id":721545,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:10:03.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":3308,"price":42.1722,"value":139505.6376,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.81 to $42.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":150914,"source":{"system":"sec-edgar","filing":"0001193125-26-292546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292546/ownership.xml","form_type":"4"}},{"id":721544,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:10:03.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":3792,"price":41.3934,"value":156963.7728,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.80 to $41.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":154222,"source":{"system":"sec-edgar","filing":"0001193125-26-292546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292546/ownership.xml","form_type":"4"}},{"id":721543,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:10:03.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1900,"price":40.0914,"value":76173.66,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.61 to $40.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":158014,"source":{"system":"sec-edgar","filing":"0001193125-26-292546","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292546/ownership.xml","form_type":"4"}},{"id":721541,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:03.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":876,"price":40.3375,"value":35335.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.26 to $40.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":548027,"source":{"system":"sec-edgar","filing":"0001193125-26-292519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292519/ownership.xml","form_type":"4"}},{"id":721540,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-01T20:05:03.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7344,"price":39.7688,"value":292062.0672,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on March 27, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.25 to $40.225, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":548903,"source":{"system":"sec-edgar","filing":"0001193125-26-292519","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526292519/ownership.xml","form_type":"4"}},{"id":743396,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:57:24.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266155/ownership.xml","form_type":"4"}},{"id":743395,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":39727,"kind":"person","name":"PEREZ ROBERT J","position":1,"cik":"0001263230","reported_name":"PEREZ ROBERT J","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:52:18.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266147","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266147/ownership.xml","form_type":"4"}},{"id":743394,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":13211,"kind":"person","name":"PAUL STEVEN M","position":1,"cik":"0001237564","reported_name":"PAUL STEVEN M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:46:23.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266129","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266129/ownership.xml","form_type":"4"}},{"id":743393,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":15694,"kind":"person","name":"Silva Paul M","position":1,"cik":"0001446372","reported_name":"Silva Paul M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:28:25.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266099","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266099/ownership.xml","form_type":"4"}},{"id":743392,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":38748,"kind":"person","name":"HEALY JAMES","position":1,"cik":"0001245624","reported_name":"HEALY JAMES","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:26:42.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266095","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266095/ownership.xml","form_type":"4"}},{"id":743391,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":39726,"kind":"person","name":"Huber Reid M","position":1,"cik":"0001607052","reported_name":"Huber Reid M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:25:37.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266090/ownership.xml","form_type":"4"}},{"id":743441,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":37762,"kind":"person","name":"Young Wendy B.","position":1,"cik":"0002042847","reported_name":"Young Wendy B.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:24:40.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266086","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2042847/000119312526266086/ownership.xml","form_type":"4"}},{"id":743390,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":39725,"kind":"person","name":"Sanchez Ramiro","position":1,"cik":"0001830326","reported_name":"Sanchez Ramiro","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:23:25.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266080","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266080/ownership.xml","form_type":"4"}},{"id":760427,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":23357,"kind":"organization","name":"Third Rock Ventures V, L.P.","position":1,"cik":"0001778071","reported_name":"Third Rock Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23358,"kind":"organization","name":"Third Rock Ventures GP V, LP","position":2,"cik":"0001977498","reported_name":"Third Rock Ventures GP V, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23359,"kind":"organization","name":"TRV GP V, LLC","position":3,"cik":"0001990717","reported_name":"TRV GP V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23360,"kind":"organization","name":"Third Rock Ventures VI, L.P.","position":4,"cik":"0001931056","reported_name":"Third Rock Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23361,"kind":"organization","name":"Third Rock Ventures GP VI, L.P.","position":5,"cik":"0001977499","reported_name":"Third Rock Ventures GP VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23362,"kind":"organization","name":"TRV GP VI, LLC","position":6,"cik":"0001990716","reported_name":"TRV GP VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-28T20:15:04.000Z","date":"2026-05-26","kind":"sale","planned":true,"acquired":false,"shares":18572,"price":40.047,"value":743752.884,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly held by Third Rock Ventures V, L.P. (\"TRV V\"). The general partner of TRV V is Third Rock Ventures GP V, L.P. (\"TRV GP V\"). The general partner of TRV GP V is TRV GP V, LLC (\"TRV GP V LLC\"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":6280525,"source":{"system":"sec-edgar","filing":"0001193125-26-245259","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526245259/ownership.xml","form_type":"4"}},{"id":781032,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":23357,"kind":"organization","name":"Third Rock Ventures V, L.P.","position":1,"cik":"0001778071","reported_name":"Third Rock Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23358,"kind":"organization","name":"Third Rock Ventures GP V, LP","position":2,"cik":"0001977498","reported_name":"Third Rock Ventures GP V, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23359,"kind":"organization","name":"TRV GP V, LLC","position":3,"cik":"0001990717","reported_name":"TRV GP V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23360,"kind":"organization","name":"Third Rock Ventures VI, L.P.","position":4,"cik":"0001931056","reported_name":"Third Rock Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23361,"kind":"organization","name":"Third Rock Ventures GP VI, L.P.","position":5,"cik":"0001977499","reported_name":"Third Rock Ventures GP VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23362,"kind":"organization","name":"TRV GP VI, LLC","position":6,"cik":"0001990716","reported_name":"TRV GP VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-13T23:06:16.000Z","date":"2026-05-11","kind":"sale","planned":true,"acquired":false,"shares":133618,"price":40.244,"value":5377322.792,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly held by Third Rock Ventures V, L.P. (\"TRV V\"). The general partner of TRV V is Third Rock Ventures GP V, L.P. (\"TRV GP V\"). The general partner of TRV GP V is TRV GP V, LLC (\"TRV GP V LLC\"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":6299097,"source":{"system":"sec-edgar","filing":"0001193125-26-222185","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526222185/ownership.xml","form_type":"4"}},{"id":785034,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":23357,"kind":"organization","name":"Third Rock Ventures V, L.P.","position":1,"cik":"0001778071","reported_name":"Third Rock Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23358,"kind":"organization","name":"Third Rock Ventures GP V, LP","position":2,"cik":"0001977498","reported_name":"Third Rock Ventures GP V, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23359,"kind":"organization","name":"TRV GP V, LLC","position":3,"cik":"0001990717","reported_name":"TRV GP V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23360,"kind":"organization","name":"Third Rock Ventures VI, L.P.","position":4,"cik":"0001931056","reported_name":"Third Rock Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23361,"kind":"organization","name":"Third Rock Ventures GP VI, L.P.","position":5,"cik":"0001977499","reported_name":"Third Rock Ventures GP VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23362,"kind":"organization","name":"TRV GP VI, LLC","position":6,"cik":"0001990716","reported_name":"TRV GP VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T21:07:03.000Z","date":"2026-05-08","kind":"sale","planned":true,"acquired":false,"shares":5018,"price":40.306,"value":202255.508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.10 to $40.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly held by Third Rock Ventures V, L.P. (\"TRV V\"). The general partner of TRV V is Third Rock Ventures GP V, L.P. (\"TRV GP V\"). The general partner of TRV GP V is TRV GP V, LLC (\"TRV GP V LLC\"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":6432715,"source":{"system":"sec-edgar","filing":"0001193125-26-217092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526217092/ownership.xml","form_type":"4"}},{"id":785033,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":23357,"kind":"organization","name":"Third Rock Ventures V, L.P.","position":1,"cik":"0001778071","reported_name":"Third Rock Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23358,"kind":"organization","name":"Third Rock Ventures GP V, LP","position":2,"cik":"0001977498","reported_name":"Third Rock Ventures GP V, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23359,"kind":"organization","name":"TRV GP V, LLC","position":3,"cik":"0001990717","reported_name":"TRV GP V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23360,"kind":"organization","name":"Third Rock Ventures VI, L.P.","position":4,"cik":"0001931056","reported_name":"Third Rock Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23361,"kind":"organization","name":"Third Rock Ventures GP VI, L.P.","position":5,"cik":"0001977499","reported_name":"Third Rock Ventures GP VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23362,"kind":"organization","name":"TRV GP VI, LLC","position":6,"cik":"0001990716","reported_name":"TRV GP VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-05-11T21:07:03.000Z","date":"2026-05-07","kind":"sale","planned":true,"acquired":false,"shares":271495,"price":40.121,"value":10892650.895,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly held by Third Rock Ventures V, L.P. (\"TRV V\"). The general partner of TRV V is Third Rock Ventures GP V, L.P. (\"TRV GP V\"). The general partner of TRV GP V is TRV GP V, LLC (\"TRV GP V LLC\"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":6437733,"source":{"system":"sec-edgar","filing":"0001193125-26-217092","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526217092/ownership.xml","form_type":"4"}},{"id":803818,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":23357,"kind":"organization","name":"Third Rock Ventures V, L.P.","position":1,"cik":"0001778071","reported_name":"Third Rock Ventures V, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23358,"kind":"organization","name":"Third Rock Ventures GP V, LP","position":2,"cik":"0001977498","reported_name":"Third Rock Ventures GP V, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23359,"kind":"organization","name":"TRV GP V, LLC","position":3,"cik":"0001990717","reported_name":"TRV GP V, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23360,"kind":"organization","name":"Third Rock Ventures VI, L.P.","position":4,"cik":"0001931056","reported_name":"Third Rock Ventures VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23361,"kind":"organization","name":"Third Rock Ventures GP VI, L.P.","position":5,"cik":"0001977499","reported_name":"Third Rock Ventures GP VI, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":23362,"kind":"organization","name":"TRV GP VI, LLC","position":6,"cik":"0001990716","reported_name":"TRV GP VI, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T23:36:04.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":426005,"price":40.317,"value":17175243.585,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2)."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These shares are directly held by Third Rock Ventures V, L.P. (\"TRV V\"). The general partner of TRV V is Third Rock Ventures GP V, L.P. (\"TRV GP V\"). The general partner of TRV GP V is TRV GP V, LLC (\"TRV GP V LLC\"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares."}],"balance_after":6709228,"source":{"system":"sec-edgar","filing":"0001193125-26-167636","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526167636/ownership.xml","form_type":"4"}},{"id":803828,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-04-21T20:55:07.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":20225,"price":39.9923,"value":808844.2675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.90 to $40.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":246426,"source":{"system":"sec-edgar","filing":"0001193125-26-167091","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526167091/ownership.xml","form_type":"4"}},{"id":808956,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-04-14T20:13:40.000Z","date":"2026-04-14","kind":"sale","planned":true,"acquired":false,"shares":10200,"price":35.0781,"value":357796.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.37 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":266651,"source":{"system":"sec-edgar","filing":"0001193125-26-154908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526154908/ownership.xml","form_type":"4"}},{"id":808955,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-04-14T20:13:40.000Z","date":"2026-04-13","kind":"sale","planned":true,"acquired":false,"shares":9165,"price":34.974,"value":320536.71,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $34.90 to $35.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":276851,"source":{"system":"sec-edgar","filing":"0001193125-26-154908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526154908/ownership.xml","form_type":"4"}},{"id":808954,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-04-14T20:13:40.000Z","date":"2026-04-10","kind":"sale","planned":true,"acquired":false,"shares":500,"price":34.98,"value":17490.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."}],"balance_after":286016,"source":{"system":"sec-edgar","filing":"0001193125-26-154908","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526154908/ownership.xml","form_type":"4"}},{"id":811670,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-04-09T20:30:27.000Z","date":"2026-04-08","kind":"sale","planned":true,"acquired":false,"shares":360,"price":34.9,"value":12564.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."}],"balance_after":286516,"source":{"system":"sec-edgar","filing":"0001193125-26-149725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526149725/ownership.xml","form_type":"4"}},{"id":824340,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:27:37.000Z","date":"2026-03-30","kind":"sale","planned":true,"acquired":false,"shares":2839,"price":28.553,"value":81061.967,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.42 to $28.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":159914,"source":{"system":"sec-edgar","filing":"0001193125-26-134684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526134684/ownership.xml","form_type":"4"}},{"id":824339,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-31T20:27:37.000Z","date":"2026-03-30","kind":"sale","planned":true,"acquired":false,"shares":7161,"price":28.0401,"value":200795.1561,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.42 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":162753,"source":{"system":"sec-edgar","filing":"0001193125-26-134684","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526134684/ownership.xml","form_type":"4"}},{"id":827496,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-03-26T20:41:16.000Z","date":"2026-03-25","kind":"sale","planned":true,"acquired":false,"shares":10115,"price":29.9906,"value":303354.919,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.90 to $30.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":286876,"source":{"system":"sec-edgar","filing":"0001193125-26-126410","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526126410/ownership.xml","form_type":"4"}},{"id":853863,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:07:30.000Z","date":"2026-03-05","kind":"sale","planned":false,"acquired":false,"shares":2014,"price":28.93,"value":58265.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares of common stock sold to satisfy taxes associated with the vesting of a restricted stock unit award previously granted to the Reporting Person. Such sales do not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.34 to $28.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":169914,"source":{"system":"sec-edgar","filing":"0001193125-26-098488","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526098488/ownership.xml","form_type":"4"}},{"id":893711,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2100,"price":29.7965,"value":62572.65,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.52 to $30.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":20729,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893710,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2983,"price":29.0443,"value":86639.1469,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":22829,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893709,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":2281,"price":29.7983,"value":67969.9223,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.56 to $30.08 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":556247,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893708,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-20T00:06:29.000Z","date":"2026-02-18","kind":"sale","planned":true,"acquired":false,"shares":3552,"price":29.0516,"value":103191.2832,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.51 to $29.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":558528,"source":{"system":"sec-edgar","filing":"0001193125-26-059886","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526059886/ownership.xml","form_type":"4"}},{"id":893770,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to Buy)","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":false,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":88080,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-05","underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893769,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-19","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":1.8,"value":10800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction involved a cash exercise of options to purchase shares of the Issuer's common stock. No shares of the Issuer's common stock were sold as part of this transaction."}],"balance_after":393075,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893768,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":2200,"price":29.5944,"value":65107.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.45 to $29.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":387075,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893767,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":5400,"price":28.9497,"value":156328.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.40 to $29.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":389275,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":893766,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-19T19:05:23.000Z","date":"2026-02-17","kind":"sale","planned":true,"acquired":false,"shares":900,"price":28.0211,"value":25218.99,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.39 to $28.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":394675,"source":{"system":"sec-edgar","filing":"0001193125-26-059883","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526059883/ownership.xml","form_type":"4"}},{"id":919667,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":67771,"kind":"person","name":"Sevigny Jeffrey","position":1,"cik":"0001778483","reported_name":"Sevigny Jeffrey","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:15:33.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":130000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001193125-26-037618","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037618/ownership.xml","form_type":"4"}},{"id":919666,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:14:58.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":428000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":428000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":428000},"source":{"system":"sec-edgar","filing":"0001193125-26-037603","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037603/ownership.xml","form_type":"4"}},{"id":919665,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":35187,"kind":"person","name":"Ignelzi Troy A.","position":1,"cik":"0001579829","reported_name":"Ignelzi Troy A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:12:21.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":148000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":148000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":148000},"source":{"system":"sec-edgar","filing":"0001193125-26-037587","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037587/ownership.xml","form_type":"4"}},{"id":919699,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:11:22.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001193125-26-037581","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526037581/ownership.xml","form_type":"4"}},{"id":919664,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T21:02:22.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":132000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":132000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":132000},"source":{"system":"sec-edgar","filing":"0001193125-26-037529","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526037529/ownership.xml","form_type":"4"}},{"id":919700,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-04T16:09:59.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":103000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":103000,"derivative":{"exercise_price":27.75,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":103000},"source":{"system":"sec-edgar","filing":"0001193125-26-037570","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526037570/ownership.xml","form_type":"4"}},{"id":933549,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-23T00:00:09.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":5083,"price":26.114,"value":132737.462,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":25812,"source":{"system":"sec-edgar","filing":"0001193125-26-019820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526019820/ownership.xml","form_type":"4"}},{"id":933548,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-23T00:00:09.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":5833,"price":26.1158,"value":152333.4614,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.83 to $26.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":562080,"source":{"system":"sec-edgar","filing":"0001193125-26-019820","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526019820/ownership.xml","form_type":"4"}},{"id":937428,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-16T16:06:03.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":200,"price":27.4,"value":5480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."}],"balance_after":395575,"source":{"system":"sec-edgar","filing":"0001193125-26-015350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526015350/ownership.xml","form_type":"4"}},{"id":937427,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-16T16:06:03.000Z","date":"2026-01-15","kind":"sale","planned":true,"acquired":false,"shares":8300,"price":26.8255,"value":222651.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.33 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":395775,"source":{"system":"sec-edgar","filing":"0001193125-26-015350","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526015350/ownership.xml","form_type":"4"}},{"id":952205,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:19:48.000Z","date":"2025-12-31","kind":"sale","planned":false,"acquired":false,"shares":2840,"price":30.05,"value":85342.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person."}],"balance_after":296991,"source":{"system":"sec-edgar","filing":"0001193125-26-002469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526002469/ownership.xml","form_type":"4"}},{"id":952204,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19581,"kind":"person","name":"Yeleswaram Krishnaswamy","position":1,"cik":"0002022156","reported_name":"Yeleswaram Krishnaswamy","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Development Officer"}}],"security":"Common Stock","published_at":"2026-01-05T21:19:48.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 4, 2024, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025."}],"balance_after":299831,"source":{"system":"sec-edgar","filing":"0001193125-26-002469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022156/000119312526002469/ownership.xml","form_type":"4"}},{"id":952208,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:20:05.000Z","date":"2025-12-31","kind":"sale","planned":false,"acquired":false,"shares":6567,"price":30.0499,"value":197337.6933,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units, and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.04 to $30.05. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":404075,"source":{"system":"sec-edgar","filing":"0001193125-26-002470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526002470/ownership.xml","form_type":"4"}},{"id":952207,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-05T16:20:05.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":false,"shares":18000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 4, 2024, the Reporting Person was granted performance-based restricted stock units (\"PSUs\") subject to the satisfaction of specified performance criteria as of December 31, 2025. The issuers Compensation Committee confirmed that the performance criteria had been met, resulting in the vesting of such PSUs effective December 31, 2025."}],"balance_after":410642,"source":{"system":"sec-edgar","filing":"0001193125-26-002470","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312526002470/ownership.xml","form_type":"4"}},{"id":963342,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":515,"price":31.0396,"value":15985.394,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.75 to $31.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":30895,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963341,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2421,"price":30.0378,"value":72721.5138,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":31410,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963340,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2147,"price":28.8425,"value":61924.8475,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":33831,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963339,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":600,"price":31.036,"value":18621.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.78 to $31.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":567913,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963338,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2792,"price":30.0365,"value":83861.908,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.72 to $30.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":568513,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":963337,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-12-18T21:11:09.000Z","date":"2025-12-17","kind":"sale","planned":true,"acquired":false,"shares":2441,"price":28.8378,"value":70393.0698,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.62 to $29.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":571305,"source":{"system":"sec-edgar","filing":"0001193125-25-324826","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525324826/ownership.xml","form_type":"4"}},{"id":967916,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T17:07:08.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":796,"price":30.6772,"value":24419.0512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.61 to $30.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":392642,"source":{"system":"sec-edgar","filing":"0001193125-25-321142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525321142/ownership.xml","form_type":"4"}},{"id":967915,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-12-16T17:07:08.000Z","date":"2025-12-15","kind":"sale","planned":true,"acquired":false,"shares":7704,"price":29.9469,"value":230710.9176,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.58 to $30.57, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":393438,"source":{"system":"sec-edgar","filing":"0001193125-25-321142","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525321142/ownership.xml","form_type":"4"}},{"id":985278,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-01T21:17:37.000Z","date":"2025-11-26","kind":"exercise","planned":true,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares underlying this option vested and became exercisable on August 7, 2024, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":105407,"derivative":{"exercise_price":1.8,"expiration_date":"2033-12-05","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001193125-25-303910","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525303910/ownership.xml","form_type":"4"}},{"id":985277,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-01T21:17:37.000Z","date":"2025-11-26","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":30.0973,"value":150486.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":171928,"source":{"system":"sec-edgar","filing":"0001193125-25-303910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525303910/ownership.xml","form_type":"4"}},{"id":985276,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":34106,"kind":"person","name":"Gault Cheryl","position":1,"cik":"0001839046","reported_name":"Gault Cheryl","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-12-01T21:17:37.000Z","date":"2025-11-26","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":1.8,"value":9000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024."}],"balance_after":176928,"source":{"system":"sec-edgar","filing":"0001193125-25-303910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525303910/ownership.xml","form_type":"4"}},{"id":996109,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2841,"price":25.437,"value":72266.517,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.23 to $25.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":35978,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996108,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2242,"price":24.9107,"value":55849.7894,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.21 to $25.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":38819,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996107,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":3056,"price":25.4303,"value":77714.9968,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.22 to $25.68 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":573746,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996106,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-11-18T21:27:41.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2777,"price":24.9246,"value":69215.6142,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.22 to $25.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":576802,"source":{"system":"sec-edgar","filing":"0001193125-25-286218","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525286218/ownership.xml","form_type":"4"}},{"id":996130,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-18T16:24:43.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":5344,"price":25.3922,"value":135695.9168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.16 to $25.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":401142,"source":{"system":"sec-edgar","filing":"0001193125-25-286212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525286212/ownership.xml","form_type":"4"}},{"id":996129,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-11-18T16:24:43.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":3156,"price":24.8399,"value":78394.7244,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.16 to $25.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":406486,"source":{"system":"sec-edgar","filing":"0001193125-25-286212","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525286212/ownership.xml","form_type":"4"}},{"id":1017709,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":755,"price":26.1721,"value":19759.9355,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.08 to $26.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":41061,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017708,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":4328,"price":25.746,"value":111428.688,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":41816,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017707,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":1186,"price":26.1392,"value":31001.0912,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.06 to $26.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":579579,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017706,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-16T20:30:03.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":4647,"price":25.724,"value":119539.428,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.06 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":580765,"source":{"system":"sec-edgar","filing":"0001193125-25-241472","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525241472/ownership.xml","form_type":"4"}},{"id":1017716,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-16T16:30:05.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":1082,"price":26.1641,"value":28309.5562,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.07 to $26.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":409642,"source":{"system":"sec-edgar","filing":"0001193125-25-241475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525241475/ownership.xml","form_type":"4"}},{"id":1017715,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":65687,"kind":"person","name":"Bredt David","position":1,"cik":"0002022087","reported_name":"Bredt David","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-16T16:30:05.000Z","date":"2025-10-15","kind":"sale","planned":true,"acquired":false,"shares":7418,"price":25.7329,"value":190886.6522,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.07 to $26.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":410724,"source":{"system":"sec-edgar","filing":"0001193125-25-241475","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022087/000119312525241475/ownership.xml","form_type":"4"}},{"id":1035722,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":700,"price":27.0429,"value":18930.03,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.02 to $27.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":46144,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1035721,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":34885,"price":26.3019,"value":917541.7815,"ownership":{"direct":false,"nature":"By Dorothy Ceesay Irrevocable Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.78 to $26.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Dorothy Ceesay Irrevocable Trust u/d/t dated March 27, 2024. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that he is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose."}],"balance_after":46844,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}},{"id":1035720,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":19566,"kind":"person","name":"Ceesay Abraham","position":1,"cik":"0001722140","reported_name":"Ceesay Abraham","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-09-19T20:05:05.000Z","date":"2025-09-17","kind":"sale","planned":true,"acquired":false,"shares":1400,"price":26.8745,"value":37624.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to Rule 10b5-1 trading plans adopted on December 12, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.74 to $27.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected."}],"balance_after":585412,"source":{"system":"sec-edgar","filing":"0001193125-25-209062","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312525209062/ownership.xml","form_type":"4"}}],"next_cursor":"2025-09-19T20:05:05.000000Z,1035720"}